feed,title,long_url,short_url
Benzinga,"Artivion Stock Plunges Apixaban Vs. Warfarin Trial Setback, Reaffirms Annual Guidance",https://benzinga.com/general/biotech/22/09/28983671/artivion-stock-plunges-apixaban-vs-warfarin-trial-setback-reaffirms-annual-guidance,https://bit.ly/3LAIwqp
Benzinga,104K Reasons To Be Bullish On Scholastic Stock,https://benzinga.com/news/22/09/28984362/104k-reasons-to-be-bullish-on-scholastic-stock,https://bit.ly/3r1vR6p
Benzinga,Massive Insider Trade At Scholastic,https://benzinga.com/news/22/09/28984361/massive-insider-trade-at-scholastic,https://bit.ly/3LGNbaf
Benzinga,Scholastic EVP Makes $299K Stock Purchase,https://benzinga.com/news/22/09/28984358/scholastic-evp-makes-299k-stock-purchase,https://bit.ly/3S9Tw0f
Benzinga,10% Owner of Retail Value Sold $153K In Stock,https://benzinga.com/news/22/09/28984356/10-owner-of-retail-value-sold-153k-in-stock,https://bit.ly/3SbLpjW
Benzinga,Massive Insider Trade At Day One Biopharmaceutical,https://benzinga.com/news/22/09/28984353/massive-insider-trade-at-day-one-biopharmaceutical,https://bit.ly/3DPpRFs
Benzinga,Day One Biopharmaceutical Director Trades Company's Stock,https://benzinga.com/news/22/09/28984347/day-one-biopharmaceutical-director-trades-companys-stock,https://bit.ly/3LF1g89
Benzinga,Paragon 28 10% Owner Trades Company's Stock,https://benzinga.com/news/22/09/28984338/paragon-28-10-owner-trades-companys-stock,https://bit.ly/3SaqOwv
